Volume 16, Number 1—January 2010
Increase in Serotype 6C Pneumococcal Carriage, United Kingdom
Highlight and copy the desired format.
|EID||Tocheva AS, Jefferies JM, Christodoulides M, Faust SN, Clarke SC. Increase in Serotype 6C Pneumococcal Carriage, United Kingdom. Emerg Infect Dis. 2010;16(1):154-155. https://dx.doi.org/10.3201/eid1601.090650|
|AMA||Tocheva AS, Jefferies JM, Christodoulides M, et al. Increase in Serotype 6C Pneumococcal Carriage, United Kingdom. Emerging Infectious Diseases. 2010;16(1):154-155. doi:10.3201/eid1601.090650.|
|APA||Tocheva, A. S., Jefferies, J. M., Christodoulides, M., Faust, S. N., & Clarke, S. C. (2010). Increase in Serotype 6C Pneumococcal Carriage, United Kingdom. Emerging Infectious Diseases, 16(1), 154-155. https://dx.doi.org/10.3201/eid1601.090650.|
To the Editor: Streptococcus pneumoniae is a major human pathogen. In 2007, Park et al. identified a novel serotype, 6C (1), which emerged from serotype 6A. A study of children in the Netherlands who had not previously received a pneumococcal vaccine found low prevalence of this newly identified serotype before the heptavalent pneumococcal conjugate vaccine Prevnar/Prevenar (PCV7) (Wyeth, Taplow, UK) was introduced (2). Studies have shown cross-protection between vaccine serotype 6B and vaccine-related serotype 6A. However, PCV7 elicits no cross-protection against serotype 6C.
The potential exists for the emergence of nonvaccine serotypes or novel clones. These serotypes and clones may be better adapted to colonize the nasopharynx, evade the human immune response, and cause disease. A recent study showed an increase in prevalence of serotype 6C pneumococci in children and a corresponding decrease in serotype 6A after introduction of PCV7 (3). We studied the underlying genetic basis for expansion of serotype 6C. Initial data from an ongoing study of pneumococcal carriage are presented.
This study was reviewed and approved by the Southampton and South West Hampshire Research Ethics Committee (B) (reference 06/Q1704/105). A total of 697 nasopharyngeal swab specimens were collected from unselected (not selected by a method) children <4 years of age in the pediatric outpatient department of a large teaching hospital in the United Kingdom. Samples were obtained during October 2006–March 2007, during implementation of PCV7 in the infant immunization schedule of the United Kingdom. During October 2007–March 2008, a total of 202 pneumococci were isolated. All pneumococci were characterized by serotype and genotype.
In the first year of this study, we identified 3 (3.1%) serotype 6C pneumococci belonging to 3 sequence types (STs): ST65, ST1714, and ST1692 (Appendix Figure). ST1714 and ST 1692 shared a common clonal complex. Only ST 65 was shared between serotype 6C and serotype 6A. In the second year, we identified 14 (13.6%) serotype 6C pneumococci belonging to 6 STs (Appendix Figure). Two of these STs, of the same ST, were from siblings. Three of them (ST1692 [n = 8], ST1714 [n = 2], and ST395 [n = 1]) were members of a common clonal complex with a predicted founder of ST395. Each of the remaining 3 STs (ST398, ST1862, and ST3460) was isolated only once. One serotype 6A isolate of ST1692 was also observed.
No serotype 6C ST65 was observed in the second year. We isolated more serotype 6C pneumococci in year 2 than in year 1 (p<0.01), which was explained mostly by a large increase in ST1692 (p<0.03) (Appendix Figure). A recent study by Nunes et al. reported serotype 6C ST1692 within a clonal complex that also included ST395 and ST1714 (4), and we identified the same clonal complex in year 2 of our study.
Our study showed a large increase in ST1692 in serotype 6C pneumococci during the implementation of PCV7 and an increase in serotype 6C. Depending on the extent of cross-protection between vaccine-related serotypes, introduction of conjugate vaccines could induce clearance or emergence of vaccine-related serotypes. This introduction could also contribute to their substitution with novel or existing serotypes that are better adapted to the ecologic niche. However, our data may only be relevant to carried pneumococci and not reflected in pneumococcal disease epidemiology. Nevertheless, the increase in serotype 6C pneumococci in the United Kingdom, which is supported by a similar observation in the United States (3), highlights the potential for emergence of serotypes not included in the current study and newly developed pneumococcal conjugate vaccines.
We thank Henry Rubery, Jessica Bennett, and Joanna Garland for collecting nasopharyngeal swabs during this study; Robert Gertz and Bernard Beall for additional serotyping; and Imperial College London for use of the Wellcome Trust pneumococcal multilocus sequence typing database.
S.C.C. was supported by Wyeth UK. J.M.C.J. has received consultancy fees from GlaxoSmithKline, UK.
- Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225–33.
- Hermans PW, Blommaart M, Park IH, Nahm MH, Bogaert D. Low prevalence of recently discovered pneumococcal serotype 6C isolates among healthy Dutch children in the pre-vaccination era. Vaccine. 2008;26:449–50.
- Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis. 2009;199:320–5.
- Nunes S, Valente C, Sa-Leao R, de Lencastre H. Temporal trends and molecular epidemiology of recently described serotype 6C of Streptococcus pneumoniae. J Clin Microbiol. 2009;47:472–4.
- Appendix Figure. Genotypes of serotype 6C pneumococci isolated from children in 2006-2007 (year 1) and 2007-2008 (year 2), United Kingdom. ST, sequence type.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Stuart C. Clarke, Molecular Microbiology and Infection, Sir Henry Wellcome Laboratories, South Block, Southampton General Hospital, Southampton SO16 6YD, UK
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 31, 2011
- Page last updated: March 31, 2011
- Page last reviewed: March 31, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)